
Clinicians weigh RCC immunotherapy choices by risk, metastasis site, and histology, citing durable outcomes with nivo-ipi and favoring TKIs after early progression.
Hormone Sensitive Metastatic Castration-Resistant Prostate Cancer
Hormone Sensitive mPC progressing to mCRPC
March 2015
H&P:
Imaging:
March 2018
